TY - JOUR T1 - Gene regulation contributes to explain the impact of early life socioeconomic disadvantage on adult inflammatory levels in two European cohort studies JF - medRxiv DO - 10.1101/2020.04.03.20050872 SP - 2020.04.03.20050872 AU - Cristian Carmeli AU - Zoltán Kutalik AU - Pashupati P. Mishra AU - Eleonora Porcu AU - Cyrille Delpierre AU - Olivier Delaneau AU - Michelle Kelly-Irving AU - Murielle Bochud AU - Nasser A. Dhayat AU - Belen Ponte AU - Menno Pruijm AU - Georg Ehret AU - Mika Kähönen AU - Terho Lehtimäki AU - Olli T. Raitakari AU - Paolo Vineis AU - Mika Kivimäki AU - Marc Chadeau-Hyam AU - Emmanouil Dermitzakis AU - Nicolas Vuilleumier AU - Silvia Stringhini Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/06/2020.04.03.20050872.abstract N2 - Individuals growing up during childhood in a socioeconomically disadvantaged family experience a higher rate of inflammation-related diseases later in life. Little is known about the mechanisms linking early life experiences to the functioning of the immune system decades later. Here we explore the relationship across social-to-biological layers of early life social exposures on levels of adulthood inflammation (C-reactive protein) and the mediating role of gene regulatory mechanisms, epigenetic and transcriptomic profiling from blood, in 2,329 individuals from two European cohort studies. Consistently across both studies, we find transcriptional activity explains a substantive proportion (up to 78%) of the estimated effect of early life disadvantaged social exposures on levels of adulthood inflammation. Furthermore, we show that mechanisms other than DNA methylation potentially regulate those transcriptional fingerprints. These results further our understanding of social-to-biological transitions by pinpointing the role of pro-inflammatory genes regulation that cannot fully be explained by differential DNA methylation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Commission [grant Horizon 2020 number 633666] and the Swiss State Secretariat for Education, Research and Innovation SERI, and by an Ambizione Grant from the Swiss National Science Foundation (PZ00P3_147998). The YFS study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS); European Research Council (grant 742927 for MULTIEPIGEN project); and Tampere University Hospital Supporting Foundation. The SKIPOGH study was supported by a grant from the Swiss National Science Foundation [grant number 33CM30-124087]. M Kivimäki is supported by the UK Medical Research Council (R024227, S011676), US National Institute on Aging (NIH, R01AG056477), NordForsk and the Academy of Finland (311492). Z Kutalik was supported by the Swiss National Science Foundation (31003A_169929). The funding sources had no involvement in the study design, data collection, analysis and interpretation, writing of the report, or decision to submit the article for publication. We are grateful to the CHARGE consortium for sharing their association summary statistics. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics for eQTLs were downloaded from https://eqtlgen.org/. Summary statistics for CRP are available upon request to the CHARGE consortium. SKIPOGH and YFS individual data are available from the PIs of the studies upon reasonable request. ER -